scholarly journals The Ink4/Arf locus is a barrier for iPS cell reprogramming

Nature ◽  
2009 ◽  
Vol 460 (7259) ◽  
pp. 1136-1139 ◽  
Author(s):  
Han Li ◽  
Manuel Collado ◽  
Aranzazu Villasante ◽  
Katerina Strati ◽  
Sagrario Ortega ◽  
...  
Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 23-23 ◽  
Author(s):  
Nevin Yusufova ◽  
Matthew R Teater ◽  
Alexey Soshnev ◽  
Andreas Kloetgen ◽  
Adewola Osunsade ◽  
...  

Somatic missense mutations in histone 1 genes occur in ~30% of follicular lymphomas and DLBCL and 85% of Hodgkin's lymphomas, with significant mutual co-occurrence among these alleles, most frequently involving H1C and H1E. We crossed constitutive H1C+/-H1E+/- mice with VavP-Bcl2 transgenic mice and observed significant acceleration of lymphomagenesis (p=0.0001). Lymphoma H1 mutations affect the H1 globular domain or C-terminus. We found that the globular domain mutants fail to insert into chromatin whereas C-ter mutants fail to compact chromatin as shown by atomic force microscopy, in vitro assembled nucleosome arrays, and FRET assays in live cells. Hence both types of mutation confer loss of function. Constitutive H1C/E knockout mice are healthy and have no overt phenotype. However, immunization with T-cell dependent antigen caused significant GC hyperplasia (p=0.013) and disruption of polarity due to expansion in the number of centrocytes. Notably, H1C/EDKO GC B-cells readily outcompeted WT GC B-cells in mixed chimera experiments indicating that they have superior fitness (p=0.0086). To understand the mechanism through which this occurs we performed RNA-seq in H1C/EDKO GC B-cells which revealed an aberrant gene expression signature composed almost entirely of transcriptional activation (n=721 upregulated and n=61 downregulated q=0.05, LFC=log(1.5)). Strikingly, these same genes are upregulated during induced pluripotency (iPS cell) reprogramming, and are normally silenced during early development by the PRC2 complex (p <0.05 to 1e-05). Indeed histone mass spectrometry showed reduced H3K27me3 (p=0.0003) and increased H3K36me2 (p =0.001) in H1C/EDKO GC B-cells. This prompted us to extensively characterize the epigenome of purified H1C/EDKO vs WT GC B-cells using High-throughput chromosome conformation capture (Hi-C), ATAC-seq, and ChIP-seq for multiple histone marks. From the topological standpoint the genome is distributed in two compartments: Compartment A, consisting of unpacked chromatin available for gene regulatory processes, and compartment B, which is highly packed, silenced and inaccessible. Beyond this organization, sets of genes are organized into boundary delimited domains called TADs that share regulatory information. Remarkably, the primary effect of H1 loss of function was the shifting of approximately 256 TADs from compartment B to compartment A (there was no A to B shift). These TADs manifested highly significant gain of chromatin accessibility by ATACs-seq and featured reciprocal loss of H3K27me3 and gain of H3K36me2. These "B to A" TADs yielded increased looping connectivity and contained the primitive stem cell genes that were upregulated. Indeed, B to A shifting enabled critical stem cell enhancers to interact with and activate various stem cell genes as shown by v4C (e.g. KLF5, PRDM5, MEIS1, etc). Most remarkably, the 3D architecture of H1C/H1EDKO GC B-cells was similar to that of intermediate stages of iPS cell reprogramming. Consistent with this finding, H1C/EDKO cells exhibited 4-fold greater reprogramming to the iPS state than WT cells after OKSM transduction, and these iPS cells exhibited reduced H3K27me3, stronger pluripotency potential, and impaired differentiation. This effect was rescued by transduction of WT H1, but not globular or C terminal domain mutant H1. Strikingly, the H1C/EDKO primitive stem cell gene expression signature was highly significantly enriched (NES 1.24, FDR<0.001) in the RNA-seq profiles of independent cohorts of DLBCL patients with histone 1 mutations, as well as H1C+/-H1E+/-;VavP-Bcl2 murine lymphomas. Consistent with acquisition of stem cell characteristics, H1C+/-H1E+/-;VavP-Bcl2 but not VavP-Bcl2 primary lymphoma cells manifested lymphoma initiating functionality after secondary transplantation into recipient animals, consistent with the notion that they may have gained stem cell functionality. Collectively, we find that H1 isoforms are bona fide lymphoma tumor suppressors. We speculate that H1 mutations are limited to GC derived lymphomas due to the stoichiometric need for H1 proteins in these rapidly dividing cells. To the best of our knowledge these are the first data to implicate disruption of topological packing order of chromatin as a cancer driver mechanism, as well as the first data to provide a mechanism whereby mature B-cells can acquire cancer stem cell-like characteristics. Disclosures Melnick: Janssen: Research Funding; Epizyme: Consultancy; Constellation: Consultancy.


2008 ◽  
Vol 2 (3) ◽  
pp. 230-240 ◽  
Author(s):  
Matthias Stadtfeld ◽  
Nimet Maherali ◽  
David T. Breault ◽  
Konrad Hochedlinger

2020 ◽  
Vol 21 (18) ◽  
pp. 6764
Author(s):  
Naomichi Tanaka ◽  
Hidemasa Kato ◽  
Hiromi Tsuda ◽  
Yasunori Sato ◽  
Toshihiro Muramatsu ◽  
...  

Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 205-205
Author(s):  
Yanfeng Liu ◽  
Hui Cheng ◽  
Linping Hu ◽  
Jing Xu ◽  
Weiping Yuan ◽  
...  

Abstract Abstract 205 Somatic cell reprogramming into a pluripotent state by the so called “iPS” technology not only holds great promise in regenerative medicine, but also provides a powerful tool to study pathological dedifferentiation processes such as tumorigenesis. In fact, the four “Yamanaka” reprogramming transcription factors used for iPS induction (Oct4, Sox2, and especially C-Myc and KLF4) are known for their direct or indirect oncogenic activities. In addition, the two most well-known tumor suppressor pathways, p53 and Rb, have been shown to also suppress iPS reprogramming. These suggest that tumorigenesis and somatic cell reprogramming may share some common mechanisms. Although it was previously reported that malignant cell lines or primary cancer cells could be reprogrammed by nuclear transfer or the iPS approach, it has not been definitively demonstrated whether primary transformed cells (not established tumor cell lines) can be reprogrammed into iPS cells with a full-term developmental potential in vivo. To this end, we first established an acute myeloid leukemia (AML) mouse model by over-expressing the human MLL (mixed lineage leukemia)-AF9 fusion gene in hematopoietic cells harvested from transgenic mice that carry the Yamanaka reprogramming factors under the control of doxycycline (Dox) (Brambrink et al., 2008). We chose MLL leukemia (a group of aggressive forms of acute leukemia with poor prognosis) because the genome of MLL leukemic cells was shown to be relatively stable, thereby increasing the likelihood of successful reprogramming of the leukemic nuclei. The purified leukemic cells were then induced into iPS cells by an addition of Dox under mouse embryonic stem cell (ESC) culture conditions. The MLL-AF9 fusion gene was present in all the iPS colonies, but its expression was silent in the established iPS cell lines. The generated iPS cell lines were similar to normal ES cells lines, as shown by both genetic and epigenetic signatures. The MLL-AF9 iPS cell lines could give rise to teratomas consisting of three germ layers after injection into a SCID mouse. More importantly, some MLL-AF9 iPS cell lines were able to produce chimeras at a high rate through blastocyst injection. Noticeably however, most chimeras developed the same type of AML within 2 months, which was correlated with re-activation of the MLL-AF9 gene. Consistently, DNA methylation of a MLL-AF9 promoter differed significantly between original leukemic cells, derived iPS cells and the re-occurred leukemic cells from the chimera mice, for which the de novo DNA methtylase, DNA3b, rather than other methylating enzymes, seemed to be responsible. RNA-seq analysis is under way to further define the target genes involved in the differences of these interchangeable cell types. In summary, this study demonstrates for the first time that primary leukemia cells can be fully reprogrammed into iPS cells with the potential of developing into three germ layers and contributing to chimeric mice. The interchangeable feature between leukemic cells and iPS cells offers a unique opportunity to define the distinct mechanisms between pluripotency and malignancy, thereby having implications for specific manipulations of iPS vs. cancer cells and particularly for selective targeting of the leukemic cells harboring a MLL fusion gene. Disclosures: No relevant conflicts of interest to declare.


2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Gaskon Ibarretxe ◽  
Antonia Alvarez ◽  
Maria-Luz Cañavate ◽  
Enrique Hilario ◽  
Maitane Aurrekoetxea ◽  
...  

The procurement of induced pluripotent stem cells, or IPS cells, from adult differentiated animal cells has the potential to revolutionize future medicine, where reprogrammed IPS cells may be used to repair disease-affected tissues on demand. The potential of IPS cell technology is tremendous, but it will be essential to improve the methodologies for IPS cell generation and to precisely evaluate each clone and subclone of IPS cells for their safety and efficacy. Additionally, the current state of knowledge on IPS cells advises that research on their regenerative properties is carried out in appropriate tissue and organ systems that permit a safe assessment of the long-term behavior of these reprogrammed cells. In the present paper, we discuss the mechanisms of cell reprogramming, current technical limitations of IPS cells for their use in human tissue engineering, and possibilities to overcome them in the particular case of dental regeneration.


Sign in / Sign up

Export Citation Format

Share Document